Literature DB >> 9751696

Reconsidering targeted toxins to eliminate HIV infection: you gotta have HAART.

E A Berger1, B Moss, I Pastan.   

Abstract

The success of highly active anti-retroviral therapy (HAART) has inspired new concepts for eliminating HIV from infected individuals. A major obstacle is the persistence of long-lived reservoirs of latently infected cells that might become activated at some time after cessation of therapy. We propose that, in the context of treatment strategies to deliberately activate and eliminate these reservoirs, hybrid toxins targeted to kill HIV-infected cells be reconsidered in combination with HAART. Such combinations might also prove valuable in protocols aimed at preventing mother-to-child transmission and establishment of infection immediately after exposure to HIV. We suggest experimental approaches in vitro and in animal models to test various issues related to safety and efficacy of this concept.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9751696      PMCID: PMC33901          DOI: 10.1073/pnas.95.20.11511

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

Review 1.  Recombinant toxins as novel therapeutic agents.

Authors:  I Pastan; V Chaudhary; D J FitzGerald
Journal:  Annu Rev Biochem       Date:  1992       Impact factor: 23.643

Review 2.  Structural characteristics and regulation of the asialoglycoprotein receptor.

Authors:  R J Stockert; A G Morell; G Ashwell
Journal:  Targeted Diagn Ther       Date:  1991

3.  Exploring how to get at--and eradicate--hidden HIV.

Authors:  J Cohen
Journal:  Science       Date:  1998-03-20       Impact factor: 47.728

4.  Anti-HIV activity of CD4-Pseudomonas exotoxin on infected primary human lymphocytes and monocyte/macrophages.

Authors:  P Ashorn; G Englund; M A Martin; B Moss; E A Berger
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

5.  Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein.

Authors:  V K Chaudhary; T Mizukami; T R Fuerst; D J FitzGerald; B Moss; I Pastan; E A Berger
Journal:  Nature       Date:  1988-09-22       Impact factor: 49.962

6.  Diversity of oligosaccharide structures on the envelope glycoprotein gp 120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9. Presence of complex-type oligosaccharides with bisecting N-acetylglucosamine residues.

Authors:  T Mizuochi; T J Matthews; M Kato; J Hamako; K Titani; J Solomon; T Feizi
Journal:  J Biol Chem       Date:  1990-05-25       Impact factor: 5.157

7.  CD4-Pseudomonas exotoxin hybrid protein blocks the spread of human immunodeficiency virus infection in vitro and is active against cells expressing the envelope glycoproteins from diverse primate immunodeficiency retroviruses.

Authors:  E A Berger; K A Clouse; V K Chaudhary; S Chakrabarti; D J FitzGerald; I Pastan; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

8.  Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.

Authors:  P Ashorn; B Moss; J N Weinstein; V K Chaudhary; D J FitzGerald; I Pastan; E A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 12.779

9.  Recombinant CD4-Pseudomonas exotoxin hybrid protein displays HIV-specific cytotoxicity without affecting MHC class II-dependent functions.

Authors:  E A Berger; V K Chaudhary; K A Clouse; D Jaraquemada; J A Nicholas; K L Rubino; D J Fitzgerald; I Pastan; B Moss
Journal:  AIDS Res Hum Retroviruses       Date:  1990-06       Impact factor: 1.723

10.  Activity of CD4-Pseudomonas exotoxin against cells expressing diverse forms of the HIV and SIV envelope glycoproteins.

Authors:  P Ashorn; B Moss; E A Berger
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992
View more
  8 in total

Review 1.  Towards an HIV cure: a global scientific strategy.

Authors:  Steven G Deeks; Brigitte Autran; Ben Berkhout; Monsef Benkirane; Scott Cairns; Nicolas Chomont; Tae-Wook Chun; Melissa Churchill; Michele Di Mascio; Christine Katlama; Alain Lafeuillade; Alan Landay; Michael Lederman; Sharon R Lewin; Frank Maldarelli; David Margolis; Martin Markowitz; Javier Martinez-Picado; James I Mullins; John Mellors; Santiago Moreno; Una O'Doherty; Sarah Palmer; Marie-Capucine Penicaud; Matija Peterlin; Guido Poli; Jean-Pierre Routy; Christine Rouzioux; Guido Silvestri; Mario Stevenson; Amalio Telenti; Carine Van Lint; Eric Verdin; Ann Woolfrey; John Zaia; Françoise Barré-Sinoussi
Journal:  Nat Rev Immunol       Date:  2012-07-20       Impact factor: 53.106

2.  Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.

Authors:  Michael J Root; Dean H Hamer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

Review 3.  Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs.

Authors:  Edward A Berger
Journal:  Curr Opin HIV AIDS       Date:  2011-01       Impact factor: 4.283

Review 4.  Curing HIV: lessons from cancer therapy.

Authors:  Ronald Mitsuyasu
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

5.  Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.

Authors:  Edward A Berger; Ira Pastan
Journal:  PLoS Pathog       Date:  2010-06-10       Impact factor: 6.823

6.  Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages.

Authors:  Matthew D Marsden; Jie Xu; Dean Hamer; Jerome A Zack
Journal:  AIDS Res Hum Retroviruses       Date:  2008-11       Impact factor: 2.205

7.  Targeted killing of virally infected cells by radiolabeled antibodies to viral proteins.

Authors:  Ekaterina Dadachova; Mahesh C Patel; Sima Toussi; Christos Apostolidis; Alfred Morgenstern; Martin W Brechbiel; Miroslaw K Gorny; Susan Zolla-Pazner; Arturo Casadevall; Harris Goldstein
Journal:  PLoS Med       Date:  2006-11       Impact factor: 11.069

8.  Cell Proteins Interacting with the Human Immunodeficiency Virus in Immunoblotting can be Detected by R5- or X4- Tropic Human Immunodeficiency Virus Particles.

Authors:  Zeina Soayfane; Bilal Houshaymi; Mamdouh H Kedees; Laurent Belec; Nadine Nasreddine
Journal:  Int J Appl Basic Med Res       Date:  2020-04-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.